Quick Answer
Atara Biotherapeutics, Inc. reported Net Income Loss of $32.69 million for the year ending 2025.
- Atara Biotherapeutics, Inc. showed an increase of +138.3% in Net Income Loss from 2024 to 2025.
- This data is from Atara Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2012: -$4.11 million | Q3 2013: -$2.54 million | Q1 2014: -$7.05 million | Q2 2014: -$4.51 million | Q3 2014: -$5.92 million | Q1 2015: -$9.16 million | Q2 2015: -$14.95 million | Q3 2015: -$11.87 million | Q1 2016: -$16.56 million | Q2 2016: -$18.88 million | Q3 2016: -$25.37 million | Q1 2017: -$25.65 million | Q2 2017: -$27.43 million | Q3 2017: -$31.10 million | Q1 2018: -$41.44 million | Q2 2018: -$50.88 million | Q3 2018: -$58.36 million | Q1 2019: -$66.26 million | Q2 2019: -$74.33 million | Q3 2019: -$71.90 million | Q1 2020: -$73.51 million | Q2 2020: -$77.46 million | Q3 2020: -$74.35 million | Q1 2021: -$78.34 million | Q2 2021: -$83.79 million | Q3 2021: -$84.66 million | Q1 2022: -$88.11 million | Q2 2022: $18.47 million | Q3 2022: -$84.09 million | Q1 2023: -$74.77 million | Q2 2023: -$71.11 million | Q3 2023: -$69.80 million | Q1 2024: -$31.75 million | Q2 2024: -$19.05 million | Q3 2024: -$21.91 million | Q1 2025: $38.01 million | Q2 2025: $2.39 million | Q3 2025: -$4.30 million.
- Over the full 13 years of available data (2013 to 2025), Atara Biotherapeutics, Inc.'s Net Income Loss has grown by 472.6%.
- Historical annual values: Fiscal year 2025: $32.69 million | Fiscal year 2024: -$85.40 million | Fiscal year 2023: -$276.13 million | Fiscal year 2022: -$228.30 million | Fiscal year 2021: -$340.14 million | Fiscal year 2020: -$306.62 million | Fiscal year 2019: -$290.98 million | Fiscal year 2018: -$230.70 million | Fiscal year 2017: -$119.49 million | Fiscal year 2016: -$79.05 million | Fiscal year 2015: -$57.22 million | Fiscal year 2014: -$28.01 million | Fiscal year 2013: -$8.77 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: